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335* Prevalence of cystic ﬁbrosis-related diabetes (CFRD) and its
microvascular complications in an adult CF population
M. Choudhury1, J. Lee1, A. Prosser1, L. Speight1, L. George1, R.I. Ketchell1.
1All Wales Adult Cystic Fibrosis Centre, Llandough Hospital, Cardiff, United
Kingdom
Introduction: Annual review including an oral glucose tolerance test (OGTT) for
CFRD and impaired glucose tolerance (IGT) was introduced at our centre in 2005
(WHO criteria). We have a referral pathway and a joint CF/DM clinic and with
increasing recognition of microvascular complications all CFRD patients are now
also offered annual retinal screening and a spot albumin/creatinine ratio (ACR),
with the following results.
Results: 62/176 (35%) have CFRD (58%F, 42%M), 22/176 (13%) have IGT.
Of the CFRD patients 44 (71%) are on treatment (38 on insulin and 6 on oral
hypoglycaemics) and 18 (29%) remain under observation.
The mean±SD age of CFRD patients on treatment is 28 yrs ±7.6, (range 16−48)
and mean±SD HbA1c 7.9%±2.4 (range 4.3−13.9). Of this selected population,
32 (73%) attended retinal screening, with complications in 50%, including mild
diabetic retinopathy (DR) in 6 (19%), moderate DR in 7 (22%) and pre-proliferative
DR in 2 (6%), one subsequently required laser treatment for diabetic maculopathy. 2
patients also had early cataracts and 4 had evidence of drusen. Those with the most
severe diabetic eye disease also had the longest duration of diabetes i.e >20 yrs for
preproliferative, 10 yrs for moderate and <5 yrs for mild or no DR.
Of the CFRD patients on treatment 35 (80%) had an ACR, 11 (31%) were consistent
with microalbuminuria. Renal impairment was also common in this group but
all had been exposed to regular IV aminoglycosides. There was no evidence of
macrovascular complications in our CFRD patients.
Conclusion: Retinopathy was common in our CFRD population and warrants
regular review whereas the contribution of CFRD and nephrotoxic therapies to
renal impairment remains to be deﬁned.
336* Impaired glucose metabolism in patients with CF during acute
exacerbations
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Background: The development of diabetes in patients with CF has been associated
with a decline in their overall clinical and pulmonary function. Patients with CF
and normoglycemia (CF-NG) have higher but still normal glucose levels in the Oral
Glucose Tolerance Test (OGTT).
Objectives: To analyze the glucose metabolism and its association with pulmonary
function in CF-NG patients speciﬁcally during exacerbations
Methods: CF-NG patients underwent an OGTT and intravenous glucose tolerance
test (IVGTT) during exacerbation and 3−4 weeks after complete resolution.
Results: Of the 10 recruited patients 2 were diabetic by OGTT and were excluded.
All 8 remaining patients displayed diabetic glucose tolerance with glucose levels of
233±8mg/dl and 262±11mg/dl at 90 and 120min during exacerbation compared
with normal levels of 154±21mg/dl, 126±20mg/dl (p< 0.002) measured during
remission. IVGTT exempliﬁed higher insulin release during exacerbation compared
with remission (min 3; 305±80pmol/l vs 216±40pmol/l). When studying the ratio
between glucose levels during exacerbation (using the area under the curve [AUC]
of OGTT) and insulin secretion capacity (AUC of 1+3min insulin in IVGTT) a
negative correlation was found (r = −0.64, p = 0.09). Furthermore, we observed a
signiﬁcant negative correlation between FEV1 during remission and glucose levels
at 2 hours after OGTT during exacerbation (r = −0.88, p = 0.002).
Conclusion: During exacerbation CF-NG patients exhibit early glucose intolerance.
A higher release of ﬁrst phase insulin suggests insulin resistance, but the failure to
normalize glucose in OGTT implies also an insulin secretion defect. Based on our
results the beneﬁt of administration of insulin in non-diabetic patients during acute
exacerbations should be considered.
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Background: Identifying cystic ﬁbrosis-related diabetes (CFRD) early is important
to prevent decline in patients’ physical health.
Purpose: The purpose of this analysis was to test a screening tool to identify
patients at most risk of developing CFRD.
Methods: The screening tool (CFRDv1) included 27 items based on clinical
experience and literature, and was completed at annual reviews. Data were entered
into an SPSS database. Retrospective evaluation compared patients with normal
and abnormal oral glucose tolerance test (OGTT) results in 2005 (n = 37), 2006
(n = 45), and both years (n = 26). Abnormal OGTT was deﬁned as a two-hour result
>7.8mmol/L.
Results: The sample’s mean age was 28 + 8 years, and 47% were female. No
differences in OGTT were found by age, gender, BMI< 20 kg/m2, unintentional
weight loss, sputum organism, increased IV requirements, enteral feeds, increased
glycated haemoglobin (HbA1c), use of itraconazole or megace, or symptoms of
hyper/hypoglycaemia. Factors that were signiﬁcantly different between patients with
normal and abnormal OGTT in one or both years were previous abnormal OGTT,
intermittent steroid use, and liver disease. Strong trends were found for difﬁculty
maintaining/gaining weight and >5% decline in spirometry.
Conclusions: Certain factors are associated with presence of an abnormal OGTT
and may indicate patients at highest risk for CFRD. The screening tool has been
revised (CFRDv2) to reﬂect these ﬁndings, which also takes into consideration more
recent relevant literature regarding ﬁbrinogen, gamma-glutamyl transferase (GGT),
and CF complications as predictive factors. It will be evaluated prospectively over
the coming year.
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Introduction: Prompt diagnosis of CF related diabetes (CFRD) is important
to prevent clinical deterioration. Oral Glucose Tolerance Testing (OGTT) has
been considered the standard screening investigation for CFRD.OGTT diagnostic
parameters for Types 1and 2 diabetes may be inappropriate for investigating CFRD.
We report our experience using serial capillary blood glucose proﬁling (SCBGP)
as a possible alternative to OGTT and Continuous Glucose Monitoring (CGMS) in
CFRD screening.
Method: Large numbers of adolescents with CF attending RHSC, Glasgow were
found to have increases in their 30-, 60- and 90-minute blood glucose values,
without fasting or 120-minute values diagnostic of Impaired Glucose Tolerance
(IGT) or Diabetes mellitus (DM). We augmented the OGTT, using serial capillary
blood glucose proﬁle (SCBGP) over a 24-hour period, samples being obtained
immediately before and one hour after meals, before bed and at 3am. Patients on
enteral feeds have additional samples pre-, mid- and post-feeds.
Results: Of 27 patients who have undergone SCBGP, two did not undergo OGTT,
one of these preferring SCBGP to assess glucose metabolism. All other patients
had non-diabetic OGTTs.15 children were found to have at least one elevated
(>11.1mmol/l) SCBGP result. Insulin therapy was clinically beneﬁcial in 3 patients
where recurrently high random SCBGP results were seen in repeated proﬁles. In one
patient, SCBGP demonstrated dietary modiﬁcation alone was sufﬁcient to resolve
hyperglycaemia.
Discussion: SCBGP proﬁling has advantages over OGTT and CGMS, including
cost, ease of use and acceptability and may play a valuable role in screening CF
patients for impaired glucose metabolism.
